Prosecution Insights
Last updated: April 19, 2026

Neurocentrx Pharma Ltd.

1 pending office actions

Portfolio Summary

1
Total Pending OAs
0
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18257384 ORAL COMPOSITIONS COMPRISING KETAMINE COMBINED WITH SUBCUTANEAL OR INTRAVENOUS KETAMINE FOR USE IN THE TREATMENT, CONTROL OR PREVENTION OF DEPRESSIVE DISORDERS WHITE, DAWANNA SHAR-DAY 1627 Non-Final OA Jun 14, 2023

Managing Neurocentrx Pharma Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month